Sarepta Therapeutics, Inc. AB3A.F Stock
Sarepta Therapeutics, Inc. Price Chart
Sarepta Therapeutics, Inc. AB3A.F Financial and Trading Overview
| Sarepta Therapeutics, Inc. stock price | 103.7 EUR |
| Previous Close | 120 EUR |
| Open | 119.65 EUR |
| Bid | 119.95 EUR x 30000 |
| Ask | 120.55 EUR x 30000 |
| Day's Range | 119.65 - 119.65 EUR |
| 52 Week Range | 59.45 - 147.06 EUR |
| Volume | 59 EUR |
| Avg. Volume | 27 EUR |
| Market Cap | 11.25B EUR |
| Beta (5Y Monthly) | 1.001408 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0.4 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 118.39 EUR |
AB3A.F Valuation Measures
| Enterprise Value | 10.58B EUR |
| Trailing P/E | N/A |
| Forward P/E | -20.881327 |
| PEG Ratio (5 yr expected) | -0.12 |
| Price/Sales (ttm) | 11.531275 |
| Price/Book (mrq) | 15.6364355 |
| Enterprise Value/Revenue | 10.842 |
| Enterprise Value/EBITDA | -19.625 |
Trading Information
Sarepta Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 1.001408 |
| 52-Week Change | 101.42% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 147.06 EUR |
| 52 Week Low | 59.45 EUR |
| 50-Day Moving Average | 119.85 EUR |
| 200-Day Moving Average | 116.52 EUR |
AB3A.F Share Statistics
| Avg. Volume (3 month) | 27 EUR |
| Avg. Daily Volume (10-Days) | 5 EUR |
| Shares Outstanding | 93.15M |
| Float | 89.11M |
| Short Ratio | N/A |
| % Held by Insiders | 4.25% |
| % Held by Institutions | 85.35% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -114.30% |
| Operating Margin (ttm) | -59.58% |
| Gross Margin | -9.26% |
| EBITDA Margin | -55.24% |
Management Effectiveness
| Return on Assets (ttm) | -11.88% |
| Return on Equity (ttm) | -142.098% |
Income Statement
| Revenue (ttm) | 975.68M EUR |
| Revenue Per Share (ttm) | 11.11 EUR |
| Quarterly Revenue Growth (yoy) | 20.20% |
| Gross Profit (ttm) | -78066000 EUR |
| EBITDA | -539008000 EUR |
| Net Income Avi to Common (ttm) | -1115218048 EUR |
| Diluted EPS (ttm) | -12.13 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.88B EUR |
| Total Cash Per Share (mrq) | 20.21 EUR |
| Total Debt (mrq) | 1.31B EUR |
| Total Debt/Equity (mrq) | 183.18 EUR |
| Current Ratio (mrq) | 4.635 |
| Book Value Per Share (mrq) | 7.652 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -433567008 EUR |
| Levered Free Cash Flow (ttm) | -144391376 EUR |
Profile of Sarepta Therapeutics, Inc.
| Country | Germany |
| State | MA |
| City | Cambridge |
| Address | 215 First Street |
| ZIP | 02142 |
| Phone | 617 274 4000 |
| Website | https://www.sarepta.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1162 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Q&A For Sarepta Therapeutics, Inc. Stock
What is a current AB3A.F stock price?
Sarepta Therapeutics, Inc. AB3A.F stock price today per share is 103.7 EUR.
How to purchase Sarepta Therapeutics, Inc. stock?
You can buy AB3A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sarepta Therapeutics, Inc.?
The stock symbol or ticker of Sarepta Therapeutics, Inc. is AB3A.F.
Which industry does the Sarepta Therapeutics, Inc. company belong to?
The Sarepta Therapeutics, Inc. industry is Biotechnology.
How many shares does Sarepta Therapeutics, Inc. have in circulation?
The max supply of Sarepta Therapeutics, Inc. shares is 96.79M.
What is Sarepta Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Sarepta Therapeutics, Inc. PE Ratio is 259.25000000 now.
What was Sarepta Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Sarepta Therapeutics, Inc. EPS is 0.4 EUR over the trailing 12 months.
Which sector does the Sarepta Therapeutics, Inc. company belong to?
The Sarepta Therapeutics, Inc. sector is Healthcare.